REGN Jan 2025 370.000 put
| Previous Close | 0.7500 |
| Open | 0.7200 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 370.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.7200 - 0.7500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksRegeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
ReutersEU approves Sanofi's Dupixent for 'smoker's lungs'
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.
GlobeNewswireDupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the European Union (EU) Approval represents the sixth approved indication for Dupixent in the EU and seventh
